Thermo Fisher Scientific (NYSE:TMO) Rating Reiterated by SVB Leerink

SVB Leerink reissued their outperform rating on shares of Thermo Fisher Scientific (NYSE:TMO) in a report published on Monday, Zacks.com reports. SVB Leerink also issued estimates for Thermo Fisher Scientific’s Q2 2021 earnings at $5.65 EPS, Q3 2021 earnings at $4.64 EPS, Q4 2021 earnings at $4.54 EPS, Q1 2022 earnings at $4.60 EPS, Q2 2022 earnings at $4.41 EPS, Q3 2022 earnings at $5.26 EPS, Q4 2022 earnings at $5.87 EPS and FY2022 earnings at $20.14 EPS.

A number of other analysts have also commented on the stock. Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $545.00 to $550.00 and gave the stock an outperform rating in a report on Wednesday, June 23rd. Zacks Investment Research cut shares of Thermo Fisher Scientific from a hold rating to a strong sell rating and set a $491.00 price target on the stock. in a research report on Monday, July 12th. The Goldman Sachs Group reduced their price target on shares of Thermo Fisher Scientific from $590.00 to $530.00 and set a buy rating on the stock in a research report on Tuesday, June 15th. They noted that the move was a valuation call. Evercore ISI lifted their price target on shares of Thermo Fisher Scientific from $525.00 to $540.00 and gave the stock an outperform rating in a research report on Friday, April 16th. Finally, KeyCorp lifted their price target on shares of Thermo Fisher Scientific from $520.00 to $555.00 and gave the stock an overweight rating in a research report on Monday, July 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the stock. Thermo Fisher Scientific presently has a consensus rating of Buy and an average target price of $537.81.

TMO opened at $514.26 on Monday. The stock’s fifty day simple moving average is $483.14. The company has a quick ratio of 1.91, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. Thermo Fisher Scientific has a 52 week low of $399.16 and a 52 week high of $532.57. The firm has a market cap of $202.12 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 1.21 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 29th. The medical research company reported $7.21 EPS for the quarter, topping analysts’ consensus estimates of $6.69 by $0.52. Thermo Fisher Scientific had a net margin of 22.08% and a return on equity of 28.95%. The firm had revenue of $9.91 billion during the quarter, compared to analyst estimates of $9.69 billion. During the same quarter in the previous year, the business earned $2.94 EPS. The business’s quarterly revenue was up 59.0% compared to the same quarter last year. Equities analysts forecast that Thermo Fisher Scientific will post 22.02 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 15th. Shareholders of record on Wednesday, September 15th will be given a dividend of $0.26 per share. The ex-dividend date of this dividend is Tuesday, September 14th. This represents a $1.04 annualized dividend and a yield of 0.20%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 5.32%.

In other Thermo Fisher Scientific news, EVP Michel Lagarde sold 34,168 shares of the business’s stock in a transaction dated Friday, May 7th. The shares were sold at an average price of $472.60, for a total transaction of $16,147,796.80. Following the sale, the executive vice president now directly owns 52,629 shares of the company’s stock, valued at approximately $24,872,465.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.44% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Morgan Stanley increased its stake in shares of Thermo Fisher Scientific by 7.3% during the 1st quarter. Morgan Stanley now owns 8,293,242 shares of the medical research company’s stock worth $3,784,871,000 after purchasing an additional 566,814 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 1.6% during the 1st quarter. Geode Capital Management LLC now owns 5,896,819 shares of the medical research company’s stock worth $2,683,200,000 after purchasing an additional 93,794 shares during the last quarter. Norges Bank acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $2,336,640,000. JPMorgan Chase & Co. increased its stake in shares of Thermo Fisher Scientific by 1.2% during the 1st quarter. JPMorgan Chase & Co. now owns 4,560,676 shares of the medical research company’s stock worth $2,081,402,000 after purchasing an additional 53,508 shares during the last quarter. Finally, Primecap Management Co. CA grew its stake in Thermo Fisher Scientific by 0.9% in the 1st quarter. Primecap Management Co. CA now owns 4,487,174 shares of the medical research company’s stock valued at $2,047,856,000 after buying an additional 41,649 shares during the last quarter. Institutional investors own 85.90% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

See Also: How is a price target determined?

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.